Background & Aims Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with
limited treatment options. Sorafenib is the only FDA-approved first-line targeted drug for
advanced HCC, but its effect on patient survival is limited. Further, patients ultimately present
with disease progression. A better understanding of the causes of sorafenib resistance,
enhancing the efficacy of sorafenib and finding a reliable predictive biomarker are crucial to
achieve efficient control of HCC. Methods The functional effects of ANXA3 in conferring …